Skip to content
naulon
Not checkedNot checked for notices yet.

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report

Chia-I Shen, MD, Yi-Chen Yeh, MD, Chao-Hua Chiu, MD

JTO Clinical and Research Reports · 2021

doi:10.1016/j.jtocrr.2021.100156 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Immune checkpoint inhibitors (ICIs) have improved the clinical outcome of NSCLC. However, immune-related adverse events (irAEs) such as pneumonitis, thyroiditis, and colitis have been reported with the increasing use of ICIs. The diagnosis of irAEs relies on exclusion. With proper management, most patients may still benefit from ICI treatment. Pleural effusion is a rare presentation of an irAE. Here, we report a patient who experienced progressive bilateral pleural effusions during the first-line treatment of cisplatin, pemetrexed, and pembrolizumab. Serial study and surgical pleural biopsy found the possible cause of irAE. His pleural effusion subsided after discontinuing therapy. IrAE may present as pleural effusion and physicians should be alert to unknown causes of pleural effusion in patients under ICI treatment.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.